HOTH - Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

Hoth Therapeutics ([[HOTH]] +5.3%) has expanded its research agreement with Virginia Commonwealth University ((VCU)) for a potential COVID-19 treatment. Based on positive preclinical results, Hoth has amended its original scientific agreement with VCU and has agreed to further develop Dr. Michael Peters' novel peptide COVID-19 Therapeutic, HT-002.Hoth has an exclusive license to this novel peptide COVID-19 therapeutic. The expanded research agreement will focus on investigating the potential of HT-002 to inhibit SARS-CoV-2 virus variants.This work will be informed by the molecular modeling of SARS-CoV-2 spike peptide sequences from strain variants, reported earlier this year.

For further details see:

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic